ArticleOncology research2020

Pivarubicin Is More Effective Than Doxorubicin Against Triple-Negative Breast Cancer In Vivo.

Leonard Lothstein et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.